Released Aug 14, 2024, after the close
10-Q filed Aug 14, 2024, 45 days after period end · 0001558370-24-012271
Q2 2024 · 10-Q
Revenue$4.00K$4.00K −98.9% vs Q2 2023−86.2% vs Q1 2024
Net Income-$3.26M-$3.26M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$172.18-$172.18 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$3,644,000N/M
Operating Cash Flowderived-$3,084,000N/M
Margins · derived
Operating margin-91100.0%−89510.5 pt vs Q2 2023
Net margin-81425.0%−79964.4 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $4.00K | $373.00K | $0.00 | $0.00 |
| Net Income | -$3.26M | -$5.45M | -$4.58M | -$5.13M |
| EPS Diluted | -$172.18 | -$0.44 | -$0.46 | -$0.56 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio Green Med Solution, Inc. · CIK 1130166 · Engraved from SEC EDGAR